GB201418984D0 - Novel drug conjugates - Google Patents

Novel drug conjugates

Info

Publication number
GB201418984D0
GB201418984D0 GBGB1418984.9A GB201418984A GB201418984D0 GB 201418984 D0 GB201418984 D0 GB 201418984D0 GB 201418984 A GB201418984 A GB 201418984A GB 201418984 D0 GB201418984 D0 GB 201418984D0
Authority
GB
United Kingdom
Prior art keywords
drug conjugates
novel drug
novel
conjugates
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB1418984.9A
Other versions
GB2531715A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abzena UK Ltd
Original Assignee
Polytherics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polytherics Ltd filed Critical Polytherics Ltd
Priority to GB1418984.9A priority Critical patent/GB2531715A/en
Publication of GB201418984D0 publication Critical patent/GB201418984D0/en
Priority to US15/517,969 priority patent/US20170290925A1/en
Priority to JP2017519848A priority patent/JP2017534612A/en
Priority to CA2963043A priority patent/CA2963043A1/en
Priority to PCT/GB2015/052953 priority patent/WO2016063006A1/en
Priority to BR112017005760A priority patent/BR112017005760A2/en
Priority to MX2017005199A priority patent/MX2017005199A/en
Priority to KR1020177010432A priority patent/KR102513926B1/en
Priority to KR1020177008924A priority patent/KR20170071485A/en
Priority to RU2017108448A priority patent/RU2017108448A/en
Priority to KR1020237038415A priority patent/KR20230158134A/en
Priority to EP15782050.7A priority patent/EP3218009B1/en
Priority to SG11201701342XA priority patent/SG11201701342XA/en
Priority to US15/517,971 priority patent/US10835616B2/en
Priority to ES15782051T priority patent/ES2960741T3/en
Priority to SG11201701384XA priority patent/SG11201701384XA/en
Priority to AU2015334717A priority patent/AU2015334717B2/en
Priority to CN201580055608.7A priority patent/CN106794259B/en
Priority to ES15782050T priority patent/ES2885854T3/en
Priority to JP2017519672A priority patent/JP6612860B2/en
Priority to CN201580057559.0A priority patent/CN107073131B/en
Priority to EP15782051.5A priority patent/EP3220956B1/en
Priority to PCT/GB2015/052952 priority patent/WO2016059377A1/en
Publication of GB2531715A publication Critical patent/GB2531715A/en
Priority to IL250644A priority patent/IL250644B/en
Priority to IL250646A priority patent/IL250646A0/en
Priority to ZA2017/01337A priority patent/ZA201701337B/en
Priority to US16/807,298 priority patent/US20200268885A1/en
Priority to US18/609,210 priority patent/US20240293549A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB1418984.9A 2014-10-14 2014-10-24 Novel drug conjugates Withdrawn GB2531715A (en)

Priority Applications (28)

Application Number Priority Date Filing Date Title
GB1418984.9A GB2531715A (en) 2014-10-24 2014-10-24 Novel drug conjugates
PCT/GB2015/052952 WO2016059377A1 (en) 2014-10-14 2015-10-08 Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg
ES15782051T ES2960741T3 (en) 2014-10-24 2015-10-08 Conjugates and conjugation reagents
AU2015334717A AU2015334717B2 (en) 2014-10-24 2015-10-08 Conjugates and conjugating reagents
SG11201701384XA SG11201701384XA (en) 2014-10-14 2015-10-08 Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg
PCT/GB2015/052953 WO2016063006A1 (en) 2014-10-24 2015-10-08 Conjugates and conjugating reagents
JP2017519848A JP2017534612A (en) 2014-10-14 2015-10-08 Method for conjugation of peptides or proteins using a reagent comprising a leaving group including a PEG moiety
MX2017005199A MX2017005199A (en) 2014-10-24 2015-10-08 Conjugates and conjugating reagents.
KR1020177010432A KR102513926B1 (en) 2014-10-24 2015-10-08 Conjugates and conjugating reagents
KR1020177008924A KR20170071485A (en) 2014-10-14 2015-10-08 Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg
RU2017108448A RU2017108448A (en) 2014-10-24 2015-10-08 CONJUGATES AND CONJUGATING REAGENTS
KR1020237038415A KR20230158134A (en) 2014-10-14 2015-10-08 Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg
EP15782050.7A EP3218009B1 (en) 2014-10-14 2015-10-08 Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg
CN201580055608.7A CN106794259B (en) 2014-10-14 2015-10-08 Method of conjugating peptides or proteins using an agent comprising a leaving group comprising a PEG moiety
US15/517,971 US10835616B2 (en) 2014-10-14 2015-10-08 Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of PEG
US15/517,969 US20170290925A1 (en) 2014-10-24 2015-10-08 Conjugates And Conjugating Reagents
CA2963043A CA2963043A1 (en) 2014-10-24 2015-10-08 Conjugates and conjugating reagents
BR112017005760A BR112017005760A2 (en) 2014-10-24 2015-10-08 conjugates and conjugation reagents
SG11201701342XA SG11201701342XA (en) 2014-10-24 2015-10-08 Conjugates and conjugating reagents
ES15782050T ES2885854T3 (en) 2014-10-14 2015-10-08 Process for the conjugation of a peptide or protein with a reagent comprising a leaving group that includes a portion of PEG
JP2017519672A JP6612860B2 (en) 2014-10-24 2015-10-08 Conjugates and conjugate reagents
CN201580057559.0A CN107073131B (en) 2014-10-24 2015-10-08 Conjugates and conjugation reagents
EP15782051.5A EP3220956B1 (en) 2014-10-24 2015-10-08 Conjugates and conjugating reagents
IL250646A IL250646A0 (en) 2014-10-14 2017-02-16 Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg
IL250644A IL250644B (en) 2014-10-24 2017-02-16 Conjugates and conjugating reagents
ZA2017/01337A ZA201701337B (en) 2014-10-24 2017-02-22 Conjugates and conjugating reagents
US16/807,298 US20200268885A1 (en) 2014-10-24 2020-03-03 Conjugates And Conjugating Reagents
US18/609,210 US20240293549A1 (en) 2014-10-24 2024-03-19 Conjugates And Conjugating Reagents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1418984.9A GB2531715A (en) 2014-10-24 2014-10-24 Novel drug conjugates

Publications (2)

Publication Number Publication Date
GB201418984D0 true GB201418984D0 (en) 2014-12-10
GB2531715A GB2531715A (en) 2016-05-04

Family

ID=52103371

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1418984.9A Withdrawn GB2531715A (en) 2014-10-14 2014-10-24 Novel drug conjugates

Country Status (1)

Country Link
GB (1) GB2531715A (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2604284A1 (en) * 2007-02-16 2013-06-19 KTB Tumorforschungsgesellschaft mbH Receptor And Antigen Targeted Prodrug
PL2872157T3 (en) * 2012-07-12 2020-07-13 Hangzhou Dac Biotech Co., Ltd Conjugates of cell binding molecules with cytotoxic agents
NO2789793T3 (en) * 2012-10-24 2018-01-27

Also Published As

Publication number Publication date
GB2531715A (en) 2016-05-04

Similar Documents

Publication Publication Date Title
IL285516B (en) Amatoxin-antibody conjugates
IL252015A0 (en) Antibody drug conjugates
ZA201704297B (en) Pyrrolobenzodiazepine-antibody conjugates
IL250189A0 (en) Anti-cdh6 antibody drug conjugates
PL3119885T3 (en) Antibody-fynomer conjugates
HUE053287T2 (en) Anti-ptk7 antibody-drug conjugates
GB201513607D0 (en) Pyrrolobenzodiazepine-antibody conjugates
PL3148591T3 (en) Nanoparticle drug conjugates
EP3220961C0 (en) Therapeutic vitamin d conjugates
GB201614443D0 (en) Targeted drug conjugates
SG11201702298VA (en) Pharmaceutical preparation
IL246349A0 (en) Factor vii conjugates
HK1257229A1 (en) Cck2r-drug conjugates
PL3270711T3 (en) Sugar-dipeptide conjugates
SG10201506686WA (en) Conjugates
GB201418984D0 (en) Novel drug conjugates
GB201419996D0 (en) Targeted drug conjugates
GB201420910D0 (en) Pyrrolobenzodiazepine-antibody conjugates
GB201419994D0 (en) Small molecule drug conjugates
GB201407533D0 (en) Targeted drug conjugates
GB201518839D0 (en) Conjugates
GB201401818D0 (en) Targeted drug conjugates
GB201513605D0 (en) Pyrrolobenzodiazepine-antibody conjugates
GB201407530D0 (en) Small molecule drug conjugates
GB201406717D0 (en) Pyrrolobenzodiazepine-Antibody conjugates

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)